WO2001012236A3 - Methods, compositions and kits for promoting recovery from damage to the central nervous system - Google Patents

Methods, compositions and kits for promoting recovery from damage to the central nervous system Download PDF

Info

Publication number
WO2001012236A3
WO2001012236A3 PCT/US2000/022843 US0022843W WO0112236A3 WO 2001012236 A3 WO2001012236 A3 WO 2001012236A3 US 0022843 W US0022843 W US 0022843W WO 0112236 A3 WO0112236 A3 WO 0112236A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
kits
compositions
damage
nervous system
Prior art date
Application number
PCT/US2000/022843
Other languages
French (fr)
Other versions
WO2001012236A2 (en
WO2001012236A9 (en
Inventor
Seth P Finklestein
Evan Y Snyder
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0013388-4A priority Critical patent/BR0013388A/en
Priority to JP2001516579A priority patent/JP2003507349A/en
Priority to CA002380953A priority patent/CA2380953A1/en
Priority to IL14817500A priority patent/IL148175A0/en
Priority to EP00955755A priority patent/EP1210106A2/en
Priority to MXPA02001719A priority patent/MXPA02001719A/en
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Priority to CNA008145091A priority patent/CN1753686A/en
Priority to AU67903/00A priority patent/AU6790300A/en
Publication of WO2001012236A2 publication Critical patent/WO2001012236A2/en
Publication of WO2001012236A3 publication Critical patent/WO2001012236A3/en
Priority to NO20020779A priority patent/NO20020779L/en
Publication of WO2001012236A9 publication Critical patent/WO2001012236A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present application relates to methods, kits and compositions for improving a subject's recovery from CNS injury. In certain aspects, methods of the invention comprise administering to a subject cells and a neural stimulant. Recovery may be manifest by improvements in sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech capability. In certain embodiments, subject methods can be used as part of a treatment for damage resulting from ischemia, hypoxia or trauma.
PCT/US2000/022843 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system WO2001012236A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2001516579A JP2003507349A (en) 1999-08-18 2000-08-18 Methods, compositions and kits that facilitate recovery from damage to the central nervous system
CA002380953A CA2380953A1 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system
IL14817500A IL148175A0 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system
EP00955755A EP1210106A2 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system
MXPA02001719A MXPA02001719A (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system.
BR0013388-4A BR0013388A (en) 1999-08-18 2000-08-18 Processes, compositions and kits to promote recovery from injuries to the central nervous system
CNA008145091A CN1753686A (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU67903/00A AU6790300A (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system
NO20020779A NO20020779L (en) 1999-08-18 2002-02-15 Methods, preparations and kits to promote healing of central nervous system damage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14956199P 1999-08-18 1999-08-18
US60/149,561 1999-08-18

Publications (3)

Publication Number Publication Date
WO2001012236A2 WO2001012236A2 (en) 2001-02-22
WO2001012236A3 true WO2001012236A3 (en) 2001-08-30
WO2001012236A9 WO2001012236A9 (en) 2002-09-06

Family

ID=22530841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022843 WO2001012236A2 (en) 1999-08-18 2000-08-18 Methods, compositions and kits for promoting recovery from damage to the central nervous system

Country Status (10)

Country Link
EP (1) EP1210106A2 (en)
JP (1) JP2003507349A (en)
CN (1) CN1753686A (en)
AU (1) AU6790300A (en)
BR (1) BR0013388A (en)
CA (1) CA2380953A1 (en)
IL (1) IL148175A0 (en)
MX (1) MXPA02001719A (en)
NO (1) NO20020779L (en)
WO (1) WO2001012236A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
DE10111486A1 (en) * 2001-03-09 2002-10-02 Ralph R Dawirs Use of one or more neuroactive substances for the treatment of Parkinson's disease
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
EP1471918B1 (en) * 2002-01-14 2017-07-19 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
CA2480423C (en) * 2002-04-08 2012-01-03 The Scripps Research Institute Truncated 24 kda basic fibroblast growth factor
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7651459B2 (en) 2004-01-06 2010-01-26 Neuronetics, Inc. Method and apparatus for coil positioning for TMS studies
US8177702B2 (en) 2004-04-15 2012-05-15 Neuronetics, Inc. Method and apparatus for determining the proximity of a TMS coil to a subject's head
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US8088058B2 (en) 2005-01-20 2012-01-03 Neuronetics, Inc. Articulating arm
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
CA2653745C (en) * 2006-06-02 2013-11-19 Pfizer Products Inc. Circulating tumor cell assay
DE102007003565B4 (en) 2007-01-24 2012-05-24 Forschungszentrum Jülich GmbH Device for reducing the synchronization of neuronal brain activity and suitable coil
US9884200B2 (en) 2008-03-10 2018-02-06 Neuronetics, Inc. Apparatus for coil positioning for TMS studies
WO2010033576A1 (en) 2008-09-16 2010-03-25 University Of Central Florida Research Foundation, Inc. Compositions for treating or delaying the onset of hair loss
WO2012121971A2 (en) * 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN103230581B (en) * 2011-11-10 2016-12-21 陈锦辉 For treating compositions and the method for traumatic brain injury
CN103421800B (en) * 2013-09-05 2015-07-22 新乡医学院 Recombinant gene, recombinant carrier and recombinant cell for treating spinal cord injuries
CN103555747B (en) * 2013-10-22 2015-04-08 深圳先进技术研究院 Gliocyte bFGF expression enhancement system, as well as construction method and application thereof
AU2015303798B2 (en) * 2014-08-15 2020-03-12 National Health Research Institutes Methods to enhance nerve regeneration utilizing neural stem cells and IL12p40

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1995024469A1 (en) * 1994-03-07 1995-09-14 Immunex Corporation Extracorporeal cell culture and transplantation kits
WO1996015224A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
WO1997034618A1 (en) * 1996-03-22 1997-09-25 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5817773A (en) * 1990-06-08 1998-10-06 New York University Stimulation, production, culturing and transplantation of stem cells by fibroblast growth factors
WO2000000588A2 (en) * 1998-06-30 2000-01-06 Diacrin, Inc. Porcine spinal cord cells and their use in spinal cord repair
WO2000069448A1 (en) * 1999-05-14 2000-11-23 Henry Ford Health System Bone marrow transplantation for treatment of stroke

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817773A (en) * 1990-06-08 1998-10-06 New York University Stimulation, production, culturing and transplantation of stem cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1995024469A1 (en) * 1994-03-07 1995-09-14 Immunex Corporation Extracorporeal cell culture and transplantation kits
WO1996015224A1 (en) * 1994-11-14 1996-05-23 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
WO1997034618A1 (en) * 1996-03-22 1997-09-25 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
WO2000000588A2 (en) * 1998-06-30 2000-01-06 Diacrin, Inc. Porcine spinal cord cells and their use in spinal cord repair
WO2000069448A1 (en) * 1999-05-14 2000-11-23 Henry Ford Health System Bone marrow transplantation for treatment of stroke

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "INTRACEREBRAL TRANSPLANTATION OF BONE MARROW WITH BDNF AFTER MCAO IN RAT", NEUROPHARMACOLOGY,PERGAMON PRESS, OXFORD,GB, vol. 39, no. 5, March 2000 (2000-03-01), pages 711 - 716, XP000938486, ISSN: 0028-3908 *
DINSMORE J ET AL: "EMBRYONIC STEM CELLS DIFFERENTIATED IN VITRO AS A NOVEL SOURCE OF CELLS FOR TRANSPLANTATION", CELL TRANSPLANTATION,ELSEVIER SCIENCE,US, vol. 5, no. 2, 1996, pages 131 - 143, XP002920536, ISSN: 0963-6897 *
EGLITIS ET AL: "HEMATOPOIETIC CELLS DIFFERENTIATE INTO BOTH MICROGLIA AND MACROGLIA IN THE BRAINS OF ADULT MICE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 94, April 1997 (1997-04-01), pages 4080 - 4085, XP002100574, ISSN: 0027-8424 *
KENNEDY T E ET AL: "NETRINS ARE DIFFUSIBLE CHEMOTROPIC FACTORS FOR COMMISSURAL AXONS IN THE EMBRYONIC SPINAL CORD", CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 78, 12 August 1994 (1994-08-12), pages 425 - 435, XP002017868, ISSN: 0092-8674 *
MARCINIAK A ET AL: "Neural stem cells, in combination with basic fibro-blast growth factor (bFGF), may represent a treatment for stroke.", EXPERIMENTAL NEUROLOGY, vol. 164, no. 2, August 2000 (2000-08-01), Seventh Annual Conference of the American Society for Neural Transplantation and Repair;Clearwater, Florida, USA; April 27-30, 2000, pages 444, XP002159565, ISSN: 0014-4886 *

Also Published As

Publication number Publication date
WO2001012236A2 (en) 2001-02-22
AU6790300A (en) 2001-03-13
JP2003507349A (en) 2003-02-25
CA2380953A1 (en) 2001-02-22
WO2001012236A9 (en) 2002-09-06
NO20020779D0 (en) 2002-02-15
NO20020779L (en) 2002-04-15
IL148175A0 (en) 2002-09-12
MXPA02001719A (en) 2003-09-25
EP1210106A2 (en) 2002-06-05
BR0013388A (en) 2002-08-27
CN1753686A (en) 2006-03-29

Similar Documents

Publication Publication Date Title
WO2001012236A3 (en) Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2000035919A3 (en) Quinoline derivatives
ATE552891T1 (en) COMBINATION OF ACID PROTEASE ZYMES AND ACID BUFFER SOLUTIONS AND THEIR USE
NO953462D0 (en) Heterocyclic compounds and their preparation and use
PH31394A (en) Certain Ä,2,5-thiadiazol-4-ylÜ-1-azabicyclo Ä3,2,1Üoctane derivaives and their pharmaceutical uses.
WO2002041889A3 (en) Indolsulfonyl compounds useful in the treatment of cns disorders
EP0384285A3 (en) Piperidine compounds and their preparation and use
CA2308216A1 (en) Use of non-immunosuppressive compounds for promoting nerve regeneration
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
CA2168829A1 (en) Paroxetine hydrochloride anhydrate forms a,b,c and d
WO2003059261A3 (en) Cosmetic composition containng carbon dioxide
AU2736888A (en) Novel sulfhydryl containing tricyclic lactams and their pharmacological methods of use
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
WO2001093849A3 (en) Treatment of gastroesophageal reflux disease using piperidine derivatives
WO1992020649A3 (en) Substituted 2-carboxyindoles having pharmaceutical activity
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2002011675A3 (en) Organic nutrient for hair loss treatment
ATE99290T1 (en) SUBSTITUTED 4-AMINO-2-BUTINYL UREAS AND THIOUREAS AND THEIR DERIVATIVES AS CENTRALLY ACTING MUSCARINES.
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
WO2000040699A3 (en) Astrocytes, their preparation and uses thereof
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
IE893230L (en) Hydrocarbon substituted pyrrolidinones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 148175

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001719

Country of ref document: MX

Ref document number: 2380953

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 67903/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000955755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008145091

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000955755

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 17 AND 34, DESCRIPTION, REPLACED BY NEW PAGES 17 AND 34; PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000955755

Country of ref document: EP